Multiple myeloma (MM) is the second most common hematological cancer and is
characterized by genetic features including translocations, chromosomal copy number …

Multiple myeloma (MM) is a hematologic malignancy characterized by the proliferation of
clonal plasma cells in the bone marrow (BM). It is known that early genetic mutations in post …

Intratumor heterogeneity as a clinical challenge becomes most evident after several
treatment lines, when multidrug-resistant subclones accumulate. To address this challenge …

Purpose: Multiple myeloma is a biologically heterogenous plasma-cell disorder. In this
study, we aimed at dissecting the functional impact on transcriptome of gene mutations, copy …

Multiple myeloma (MM) is a genetically complex and heterogeneous neoplasm in which
cytogenetics is a major factor playing an important role in the risk stratification of disease …

Multiple myeloma (MM) is a genetically heterogeneous disease and the management of
relapses is one of the biggest clinical challenges. TP53 alterations are established high‐risk …

Immunotherapy is now standard of care for multiple myeloma, where the most common
targets are B cell maturation antigen, CD38, and G protein-coupled receptor class C group 5 …

For the treatment of Multiple Myeloma, proteasome inhibitors are highly efficient and widely
used, but resistance is a major obstacle to successful therapy. Several underlying …

Although treatment of multiple myeloma has changed dramatically over time, there is still a
subpopulation of patients who do not respond to treatments and are labeled as high risk. A …

In dieser Arbeit wurde ein modulares Zelllinienmodell zur Visualisierung klonaler
Evolutionsmechanismen etabliert. Hierfür wurden unterschiedlich fluoreszierende Proteine …